medigraphic.com

1993, Número 2

Siguiente >>

Vet Mex 1993; 24 (2)


Quinolonas y fluoroquinolonas en medicina veterinaria

Sumano LH

Idioma: Español/Inglés
Referencias bibliográficas: 73
Paginas: 83-92
Archivo PDF: 1033.85 Kb.


FRAGMENTO

lntroducción

En la actualidad, la mayoria de los medicamentos que ingresan al mercado veterinario tienen un origen sintético, o por lo menos biosintético. Para que se cuente con una nueva molécula original y con actividad farmacológica superior se requiere haber estudiado por lo menos unas 3,000 moléculas por año en el laboratorio de desarrollo, con sistemas de diseño por computadora y retroalimentación de este paso con los bioensayos in vitro e in vivo. Se calcula que un equipo de investigación con quimicos, médicos veterinarios, biológos, bioquimicos y técnicos de apoyo, requieren un promedio de 5 años para liberar un medicamento al mercado veterinario. En este momento se conoren los detalles relevantes de la farmacocinética del nuevo fármaco en la especie particular en la que será aplicado, incluyendo detalles de toxicidad, biodisponibilidad, velocidad de depuración, tasa de acumulación de residuos, sinergias y antagonismos, estabilidad, irritación a tejidos, espectro antibacteriano y muchos otros detalles que permiten liberar una "indicación" especifica (claim en inglés).


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Albrecht, R.: Development of antibacterial agents of the nalidixic acid type. Prog. Drug Res., 21: 99-104 (1977).

  2. Al-Orainey, I.O., Bashandi, A.M. and Saeed, E.N.S.: Failure of ciprofloxacin to eradicate brucellosis in experimental aninia1s. J Chemother., 2: 380-383 (1990).

  3. Anadón, A., Martinez-Larrañaga, M.R., Diaz M.J., Velez, C. and Bringas, P.: Pharmacokinetics of pipemidic acid in chicken after single intravenous and oral dosing. Am. J. vet. Res., 51: 1756-1759 (1990).

  4. Anadón, A., Martinez-Larrañaga, M.R., Diaz, M.J., Velez, C. and Bringas, P.: Pharmacokinetic and residue studies of quinolone compounds and olaquindox in poultry. Ann. Rech. Vet., 21 (Suppl. 1): 137s-144s (1990).

  5. Bergan, T.: Quinolones. In: Antimicrobial Agents Annual 2. Edited by: Peterson, P.K., Verhoef J., 169-183. Elsevier, Amsterdam, Holland, 1987.

  6. Booth, N. and McDonald, L.: Veterinary Pharmacology and therapeutics. 5th ed. Iowa State University Press, Ames, Iowa, 1982.

  7. Brown, D.A., Vooper, J., Gauze, J.J., Greco, D.S., Weise, D.W. and Buck, J.M.: Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. Am. J vet. Res., 51: 1065-1070 (1990).

  8. Burkhandt, J.E., Hill, M.A., Carlton, W.W. and Kesterson, J.W.: Histologic and histochemical changes in articular cartilages of immature Beagle dogs dosed with difloxacin, a fluoroquinolone. Vet. Pathol., 27: 162-170 (1990).

  9. Chin, N.X. and Neu, H.C.: In vitro activity of enoxacin, aquinolone carboxylic acid, compared with those of norfloxacin, new B lactams, aminoglycosides, and trimethoprim. Antimicrob. Agents Chemother., 24: 754-763 (1983).

  10. Chin, N.X. and Neu, H.C.: Ciprofloxacin, aquinolone carboxylic acid compoundactive against aerobic bacteria. Antimicrob. Agents Chemother., 25 319-326 (1984).

  11. Christ, W., Lehnert, T. and Ulbrich, B.: Specific toxicologic aspects of the quinolones. Rev. Infect. Dis., 10 (Suppl. 1): 141s-146s (1988).

  12. Chu, D.T.W., Fernandes, P.B. and Pernet, A.G.: Synthesis and biological activity of benzothiazolo (3, 2-a) quinolone antibacterial agent. J. Med. Chem., 29: 1531-1534 (1986).

  13. Chu, D.T.W. and Fernandes, P.B.: Structure activity relationships of the fluoroquinolones. Antimicroh. Agents Chemother., 33; 131-135 (1989).

  14. Cornett, J.B., Wagner, R.B., Dobson, R.A. Wentland, M.P. and Bailey, D.M.: In vitro and vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin). Antimicrob. Agents Chemother., 27: 410 (1985).

  15. Crumplin, G.C., Kenwright, P. and Hirst, T.: Investigation into the mechanism of action of the antibacterial agent norfloxacin, J. Antimicrob. Chemother., 8: 251-261 (1984).

  16. Crumplin, G.C. and Simth, J.T.: Nalidixic acid: An antibacterial paradox. Antimicrob. Agents Chemother., 8: 251-261 (1975).

  17. Domagala, J.M., Hanna, L.D., Heifetz, C;.L., Huff, M.P., Mich, T.F., Sanchez, P. and Solomon, M.: New structure activity relationship of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. J. Med. Chem., 29: 704-404 (1986).

  18. Dow, S.W. and Papich, M.G.: An update on antimicrobials: New uses, modifications and developments. Vet. Med., 85: 707-715

  19. Drilca, K.: Biology of bacterial deoxiribonucleic acid topoisomerases. Microbiol. Rev., 48: 273-289 (1984).

  20. Endtz, H.P., Rujjs, G,J., Klingeren van, B., Jansen, W.H., Rryden van der, T. and Mouton, R.P.: Quinolone in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob. Chemother., 27: 199-208 (1991).

  21. Frame, G.M., Mann, D.D. and Lynch, M.J .:Pharmacokinetc of quinolone antibiotic danofloxacin (CP-76,136) in cattle swine and poultry. Abstracts of the 29th Interscience Conference on Antimicrobial Agents and chemotherapy. Houston, Texas. 1989. 127-128. Omnipress. Madison, Wisconsin (1989).

  22. Gargallo, D., Moros, M., Coll, R., Esteve, M., Pares, J., Xicota, M.A. and Guinea, J.: Activity of E-3846, a new fluoroquinolone and in experimental cystitis and phyelone phritis in rats. Antimicrob. Agents Chemother., 39: 636-641 (1988).

  23. Gede, K.W.: Antibacterial activity of newer quinolones and nalidixic acid against bovine mastitis pathogens. Dt. Tieraerztl Wochenschr., 94: 545-548 (1987).

  24. Gelleret, M: DNA topoisomerases. Ann. Rev. Biochem., 50: 879-910 (1981).

  25. Georgopapadaku, N.H., Dix, B.A., Angerhn, P., Wick, A. and Olson, G.L.: Monocyclic and tricyclic analogues of quinolones: Mechanism of action. Antimicrob. Agents Chemother., 31: 614-616 (1987).

  26. Giles, C.J., Grimshaw, W.T.R., Shanks, D.J. and Smith, D.C.: Efficacy of danofloxacin in the therapy of acute bacterial pneumonia in housed beef cattle. Vet. Rec., 128: 296-300 (1991).

  27. Giles, C.J., Magonigle, R.A., Grimshaw, W.T.R., Tanner, A.C., Risk, J.E., Lynch, M.J. and Rice, J.R.: Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. J. vet. Pharmacol. Therap., 14: 400-410 (1991).

  28. Cambert, M.E., Aulicino, T.M., Bouchet Du, L. and Berkowits, L.B.: Susceptibility of Nocardia asteroides to new quinolone and beta-lactams. Antimicrob. Agents Chemother., 31: 2013-2014 (1987).

  29. Greene, C.E.: New developments in antimicrobial therapy. Proceedings of the Tenth Annual Veterinary Medical Forum. 1992.93-96. Blacksburg, Virginia. Omnipress. Madison, Wisconsin (1992).

  30. Hannan, P.C.T. and Goodwin, R.F.W.: Treatment of experimental enzootic pneumonia of the pig by norfloxacin or its 6-chloro analogue. Res. vet. Sci., 49: 203-210 (1990).

  31. Hannan, P.C.T., O’Hanlon, P.J. and Rogers, N.H.: In vitro evaluation of varius quinolone antibacterial agents against veterinary Mycoplasmas and porcine respiratory bacterial pathogens. Res. vet. Sci., 46: 202-211 (1989).

  32. Hinz, K.T. and Rottman, S.: Studies in vivo on the efficacy of enrofloxacin against Mycoplasma gallisepticum. Avian Pathol., 19: 511-522 (1990).

  33. Holmes, B., Brodgen, R.N. and Richards, D.M.: Norfloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs, 30: 482-513 (1985).

  34. Houston, D.M., Parent, J. and Matushek, K.: Ivermectin toxicosis in a dog. J Am. vet. med. Ass., 191: 78-80 (1987).

  35. Innoue, S.J., Yamagishi, S., Nakamura, S., Furutani, Y. and Shimizu, M.: Novel nalidixic acid-resistance mutations relating to DNA-gyrase activity. In: Drug Resistance in Bacteria. Edited by: Mitsuhashi, S., 411-414. Thieme Stratton, New York, 1982.

  36. Ito, A., Hirai, K., Inoue, M., Koga, H., Suzue, S., Irikure, T. and Misuhashi, S.: In vitro antibacterial activity of AM-715 a new nalidixic acid analogue. Antimicrob. Agents Chemother., 17: 103- 108 (1980).

  37. Jefson, M.R. and McGuirk, P.R.: Danofloxacin mesylate advocin (CP-76136-27), a veterinary antibacterial fluoroquinolone. Drug Futures, 129397 (1992).

  38. King, A., Shannon, K. and Phillips, I.: The in vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid. J Antimicrob. Chemother., 13 325-331 (1984).

  39. Klinge, E., Mannisto, P.T. and Mantyla, R.: Single and multiple close pharmacokinetics of pipemidic acid in normal human volunteers. Antimcrob. Agents Chemother., 26: 69-73 (1984).

  40. Krueger, J.H. and Walker, G.C.: GroEL and dnaK genes of Escherichia coli are induced by UV irradiation and nalidixic acid in an htpR+ -dependent fashion. Proc. Natl. Acad. Sci., 81: 14999-1503 (1984).

  41. Leysen, D.C., Haemers, A. and Pattyn, S.R.: Mycobacteria and the new quinolones. Antimicrob. Agents Chemother., 33 1-5 (1989).

  42. Mann, D.D. and Frame, G.M: Pharmacokinetic study of danofloxacin in cattle and swine. Am. J vet. Ra., 53: 1022-1026 (1992).

  43. McGuirk, P.R.,Jefson, M.R., Mann, D.D., Elliot, N.C., Chang, P., Cicek, EP., Cornell, C.P., Gootz, T.D. Haskell, D.L., Hindahl, M.S., Laflewr, L.J., Rosenfeld, M.J., Shuyock, T.R., Silva, A.M. and Wetter, F.H.: Synthesis and structure-activity relationships of 7- diazabicycloalkylquinolones including danofloxacin, a new quinolone antibacterial agent for veterinary medicine. J med. Chem, 35 611-620 (1992).

  44. Mevius, D.J., Breukink, H.J., Miert van, A.S.J., Kessels, B.G.F., Jobse, AS. and Smit, J.A.H.: Effects of experimentally induced Pasteurella haemolytica infection in dairy calves on the pharmacokinetics of flumequine. J vet. Pharm. Ther., 14: 174-184 (1990).

  45. Miyamoto, T., Matsumoto, J., Chiba, K., Egawa, H., Shibamori, K, Minamida, A., Nishimura, Y., Okada, H., Katoaka, M., Fujita, M., Hirose, T. and Nakano, J.: Synthesis and structure-activity relationships of 5-substituted 6, 8-difluoroquinolones, including sparfloxacin: A new antibiotical agent with improved potency. J Med. Chem., 33.1645-1656 (1990).

  46. Neer, M.T.: Clinical pharmacologic features of fluoroquinolone antimicrobial drugs. J Am. vet. med. Ass., 193: 577-580 (1988).

  47. Neer, M.T.: Cervical pain in the small breed dog. In: Proceedings of the Tenth Annual Veterinary Medical Forum. Blacksburg, Virginia. 1992. 376-379. Omnipress. Madison, Wisconsin (1992).

  48. Nouws J.F.M., Mevius, D.J., Vree, T.B., Baars, A.M. and Laurensen, J.: Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. Vet. Q., 10: 156-163 (1988).

  49. Pérez-Martínez, JA: Las quinolonas: Estructura química, mecanismo de acción bactericida y perfil de farmacología clínica. Vet. Méx., 23 57-66 (1992).

  50. Piddock, L.J.V., Wray, C., McClaren, I. and Wise, R.: Quinolone resistance in Salmonella spp: Veterinary pointers. Lancet, 336: 123-125 (1990).

  51. Prescott J.F. and Welding, K.M.: In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin and norfloxacin. Can. J vet. Res., 54: 195-197 (1990).

  52. Rosychuk, R.A.W.: New therapies in veterinary dermatology. In: Proceedings of the Tenth Annual Veterinary Medical Forum. Blacksburg, Virginia. 1992. 119-124. Omnipress. Madison, Wisconsin (1992).

  53. Sala, V. and Bertoldini, G.: Activity of a new quinolone (enrofloxacin) against Campylobacter coli and Campylobacter jejuni from pigs. Prax. vet. Milano, 10: 10-11 (1989).

  54. Schroeder, J.: Enrofloxacin: A new antimicrobial agent. Tydskr. S. Afr. vet. Ver., 61: 122-124 (1989).

  55. Sepiurka, L.J.: Eficiencia de la enrofloxacina en la resolución de diversas patologias caninas y felinas. Rev. Vet. Arg., 8: 475-479 (1991).

  56. Soback, S., Ziv, G., Winkier, M. and Saran, A.: Efficacy of parenteral dry cow therapy for S. aureus udder infections. Isr. J. vet. Med., 45 194-195 (1990).

  57. Specht, T.E. and Frederick, G.: Quinolone induced arthropathy in immature Equidae. J. Am. vet. med. Ass., 198: 516-517 (1991).

  58. Sumano, H.: Farmacología Clínica en Bovinos. Fac. de Med. Vet. y Zoot., Universidad Nacional Autónoma de México, México, D.F., 1990.

  59. Sumano, H. y Ocampo, L.: Farmacología Veterinaria. McGrawHill, Mexico, D.F., 1987.

  60. Takahashi, I., Yoshida, T., Honma, Y. and Saito, E.: Comparison of the susceptibility of Haemophilus paragallinarum to ofloxacin and other existing antimicrobial agents. J Jpn. vet. med. Ass., 43 187-191 (1990).

  61. Tulkens, P.M.: Target drugs for the treatment of intracellular infections. In: New Insights Into the Pathogenesis of Mastitis. Edited by: Burvenich, C., Vandeputte-van, M.G., Hill, A.W., 163-168. Rijksuniversiteit Gent, Gent, Belgica, 1991.

  62. Vancutsem, P.M., Babish, J.G. and Schwark, W.S.: The fluoroquinolone antimicrobials: Activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet., 80: 73-186 (1990).

  63. Walker, R.D., Stein, G.E., Hauptman, J.G., MacDonald, K.J., Budsber, S.C. and Rosser, E.J.: Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. Am. J. vet. Res., 51: 896-900 (1990).

  64. Wesser, J. and Wiedemann, B.: Inhibition of R-plasmid in Escherichia cold by 4-quinolones. Antimicrob. Agents Chemother., 31: 531-534 (1987).

  65. Williams, P.D. and Helton, D.R.: The proconvulsive activity of quinolone antibiotics in an animal model. Toxicol. Lett. (Amt.), 58: 23-28 (1991).

  66. Winter, T.: Minimum inhibitory concentrations of cefacetrill, enrofloxacin (Baytril) and gentamicin against mastitis streptococci. Inaugural-Dissertation. Tieraztliche Fakultat. Ludwig-Maximilians-Universitat. Munchen, Germany, 1988.

  67. Wolfson, S.J. and Hooper, C.D.: The fluoroquinolones: Structures, mechanisms of action, resistance and spectra of activity in dm. Antimicrob. Agents Chemother., 28: 581-586 (1985).

  68. Wray, C., Piddock, L:J.V. and McLaren, I.M.: Nalidixic acid-resistant salmonellas from animals. J. Med. Microbiol., 34:4 (1991).

  69. Yancey, R.J. Jr., Sanchez, M.S., Rzepkowski, RA., Chester, D.T., Barnes, R.E. and Ford, C.W.: Therapy of chronic staphylococcal mastitis. In: New Insights Into the Pathogenesis of Mastitis. Edited by: Burvenich, C., Vandeputte-van, M.G., Hill, A.W., 187- 204. Rijksuniuersiteit Gent, Ghent, Belgica, 1991.

  70. Yazawa, K., Mikami, Y. and Uno, J.: In vitro susceptibility of Nocardia spp to a new fluoroquinolone tosufloxacin (T-3262). Antimicrob. Agents Chemother., 33: 2140-2141 (1989).

  71. Ziv, G. and Marcus, M.P.H.: Clinical pharmacology of oxolinic acid in yoring dairy calves. Am. J vet. Res., 37: 513-515 (1976).

  72. Ziv, G., Soback, A., Kurtz, B., Glickman. A. and Winkler, M.: Concentrations of antibacterial quinolones in blood and milk. Isr. J. vet. Med., 45: 209-210 (1990).

  73. Ziv. G., Soback, A., Bor, A. and Kurtz, B.: Clinical pharmacokinetics of flumequine in calves. J. vet. Pharmacol, 9: 171-182 (1986).




2020     |     www.medigraphic.com